Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.67 |
| ▸ | PDE4A | P27815 | 14/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588075 | 0.84 | PDE4D (0.68) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6586279 | 0.81 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4365083 | 0.80 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6586317 | 0.80 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6583914 | 0.76 | PDE4A (0.47) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4371694 | 0.74 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6585673 | 0.73 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4369695 | 0.71 | PDE4B (0.67) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6586114 | 0.70 | PDE4D (0.51) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4366179 | 0.68 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498160-B2 | FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-12-24 | — | — | US | disclosed |
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-05-16 | — | — | US | disclosed |
| US-6340684-B1 | TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-01-22 | — | — | US | disclosed |
| EP-1098886-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005219-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 7/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.